GlobalPost |
FDA warns of increased risks of asthma drug Xolair
AAP News (subscription) Patients receiving the asthma medication Xolair (omalizumab) may have a slightly higher risk of serious adverse events affecting the cardiovascular and cerebrovascular systems, according to a review by the Food and Drug Administration (FDA). In … FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events |
View full post on asthma – Google News